Référentiel des médicaments
Sparsentan
Sparsentan is a medicine in the class genitourinary. It is used for nephropathy.
- Classe médicamenteuse: Genitourinary
- Indications: nephropathy
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Genitourinary
- Code ATC
- C09XX01
- Formes courantes
- comprimé
- Interactions connues
- 139 (Contre-indiquée: 24 · Majeure: 30 · Modérée: 68 · Mineure: 17)
- Noms commerciaux
- 2
- Pays et marchés
- 2
Indications
Mécanisme d'action
Single molecule that antagonizes the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), both thought to be involved in the pathogenesis of IgAN and FSGS.
Posologie adulte habituelle (résumé de la notice)
IgAN (adults): start 200 mg orally once daily; after 14 days increase to 400 mg once daily, as tolerated
Grossesse et allaitement
- Grossesse
- Unsafe Contraindicated in pregnancy: in rats it caused craniofacial and skeletal malformations and fetal death at 10 times human exposure (endothelin and angiotensin blockade). Exclude pregnancy before and during treatment; use effective contraception until 1 month (EU) or 2 weeks (US) after stopping.
- Allaitement
- Unknown No human milk data. US label: do not breastfeed (possible infant low blood pressure); EU: should not be used while breastfeeding. LactMed has no data and repeats the maker's advice. Prefer not to breastfeed during treatment.
Effets indésirables signalés
- Hyperkalemia
- Hypotension (including orthostatic hypotension)
- Peripheral edema
- Dizziness
- Anemia
- Acute kidney injury
Mises en garde encadrées
- Hepatotoxicity: available only through the restricted FILSPARI REMS. Aminotransferase elevations of at least 3-times ULN occurred in up to 3.5% of patients. Measure transaminases and bilirubin before treatment and every 3 months; interrupt and monitor if above 3-times ULN. Generally avoid in patients with baseline aminotransferases above 3-times ULN.
Contre-indications
- Pregnancy
- Concomitant use with ARBs, ERAs, or aliskiren
Précautions particulières
- Hepatotoxicity: monitor aminotransferases and bilirubin; stop and seek medical attention if symptoms of liver injury occur.
- Hypotension: consider adjusting other antihypertensives; consider dose reduction or interruption if it develops.
- Acute kidney injury: monitor kidney function periodically; patients with renal artery stenosis, CKD, severe heart failure or volume depletion are at particular risk.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (139)
- Aliskiren + Sparsentan Contraindicated
- Amlodipine-hydrochlorothiazide-valsartan + Sparsentan Contraindicated
- Amlodipine-olmesartan + Sparsentan Contraindicated
- Amlodipine-olmesartan-hydrochlorothiazide + Sparsentan Contraindicated
- Amlodipine-valsartan + Sparsentan Contraindicated
- Azilsartan + Sparsentan Contraindicated
- Azilsartan-chlorthalidone + Sparsentan Contraindicated
- Bosentan + Sparsentan Contraindicated
- Candesartan + Sparsentan Contraindicated
- Candesartan-hydrochlorothiazide + Sparsentan Contraindicated
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Sparsentan : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
- IV preparation and dilution
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Questions fréquentes
What is Sparsentan used for?
Sparsentan is a medicine in the class genitourinary. It is used for Nephropathy.
What side effects have been reported with Sparsentan?
Hyperkalemia, Hypotension (including orthostatic hypotension), Peripheral edema, Dizziness, Anemia, Acute kidney injury. Serious warning: Hepatotoxicity: available only through the restricted FILSPARI REMS.
Can Sparsentan be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Contraindicated in pregnancy: in rats it caused craniofacial and skeletal malformations and fetal death at 10 times human exposure (endothelin and angiotensin blockade). Exclude pregnancy before and during treatment; use effective contraception until 1 month (EU) or 2 weeks (US) after stopping. Breastfeeding: Unknown. No human milk data. US label: do not breastfeed (possible infant low blood pressure); EU: should not be used while breastfeeding. LactMed has no data and repeats the maker's advice. Prefer not to breastfeed during treatment.
What does Sparsentan interact with?
MediHelp lists 139 known interactions for Sparsentan. Contraindicated: 24 · Major: 30 · Moderate: 68 · Minor: 17. The most serious include Aliskiren, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
